Search results for "Lymph"

showing 10 items of 4590 documents

Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines a…

2021

Summary Purpose In the ACOSOG Z0011 trial, patients with primary breast cancer and 1–2 tumor-involved sentinel lymph nodes (SLNs) undergoing breast-conserving surgery had no oncological outcome benefit after axillary lymph node dissection (ALND), despite a relevant rate of non-SLN metastases of 27%. According to the St Gallen expert consensus, and NCCN and ASCO clinical guidelines, ALND may be avoided in patients who meet all ACOSOG Z0011 inclusion criteria. This recommendation can also be extended to patients undergoing mastectomy, with 1 or 2 positive SLNs and an indication for chest wall radiation, in whom axillary radiotherapy can be proposed as an alternative to completion ALND. The ai…

AdultCancer Researchmedicine.medical_specialtyLymphovascular invasionmedicine.medical_treatmentSentinel lymph nodeBreast NeoplasmsCohort StudiesBreast cancermedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyMastectomySocieties MedicalAgedAged 80 and overbusiness.industryAxillary Lymph Node DissectionCancerHematologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseUnited StatesOncologyLymphatic MetastasisAxillaPractice Guidelines as TopicLymph Node ExcisionFemaleGuideline AdherenceRadiologySentinel Lymph NodebusinessMastectomyBulletin du Cancer
researchProduct

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results …

2010

This study evaluated the effects of epoetin alfa on patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy. Early intervention with epoetin alfa was well tolerated and improved anemia-related patient-reported outcomes.

AdultCancer Researchmedicine.medical_specialtySurvivalAnemiaPopulationAntineoplastic AgentsBreast NeoplasmsAcademia–Pharma Intersectlaw.inventionbreast cancer; anemia; erythropoietin; hemoglobin; survival; fatigueHemoglobinsBreast cancerRandomized controlled trialstomatognathic systemlawInternal medicinehemic and lymphatic diseasesBreast CancermedicineClinical endpointHumansBlood TransfusionHemoglobinProspective StudieseducationSurvival rateErythropoietinFatigueAgededucation.field_of_studybusiness.industryEpoetin alfavirus diseasesAnemiaMiddle Agedmedicine.diseasedigestive system diseasesRecombinant ProteinsSurgeryEpoetin AlfaOncologyErythropoietinHematinicsFemalebusinesstherapeuticsmedicine.drug
researchProduct

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients…

2008

Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM). A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome. In all, 48 of the 64 LPL patients fulfilled the criteria of WM. Patients were randomly assigned to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n=34) or CHOP (n=30). R-CHOP resulted in significantly highe…

AdultCancer Researchmedicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentCHOPGastroenterologyDisease-Free SurvivalLymphoplasmacytic LymphomaAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineimmune system diseasesPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideAgedChemotherapybusiness.industryRemission InductionAntibodies MonoclonalHematologyMiddle Agedmedicine.disease3. Good healthLymphomaSurgeryTreatment OutcomeOncologyDoxorubicinVincristine030220 oncology & carcinogenesisPrednisoneRituximabWaldenstrom MacroglobulinemiaRituximabbusiness030215 immunologymedicine.drugLeukemia
researchProduct

Axillary Nodal Burden in Breast Cancer Patients With Pre-operative Fine Needle Aspiration-proven Positive Lymph Nodes Compared to Those With Positive…

2019

BACKGROUND/AIM: Recent years have seen a considerable shift to a more conservative management of the axilla in patients with positive axillary sentinel lymph nodes. The aim of this study was to determine whether some breast cancer patients with a preoperative ultrasound-guided needle aspiration biopsy proven positive node could potentially be spared an axillary lymph node dissection according to the ACOSOG Z0011 trial criteria. PATIENTS AND METHODS: A retrospective review was performed involving 623 breast cancer patients who underwent axillary lymph node dissection after either ultrasound-guided needle aspiration biopsy proven positive node or sentinel lymph node biopsy. RESULTS: Patients …

AdultCancer Researchmedicine.medical_specialtyaxillary nodal burdenCytodiagnosisSentinel lymph nodeBiopsy Fine-NeedleBreast NeoplasmsSensitivity and SpecificityGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerBiopsyPreoperative CareMedicineHumansBreastsentinel lymph node biopsyEndoscopic Ultrasound-Guided Fine Needle AspirationAgedRetrospective StudiesPharmacologyAged 80 and overmedicine.diagnostic_testbusiness.industryAxillary Lymph Node DissectionReproducibility of ResultsMiddle Agedmedicine.diseaseAxillaFine-needle aspirationmedicine.anatomical_structure030220 oncology & carcinogenesisLymphatic MetastasisAxillaFemaleRadiologyLymphLymph NodesbusinessNODALResearch Article
researchProduct

Primary Orbital Liposarcoma in Li-Fraumeni Cancer Family Syndrome: A Case Report

2005

Aims and background The aim of this study was to describe a case of primary orbital liposarcoma in Li-Fraumeni syndrome. Methods and study design In July 1998 a 20-year-old woman with a histological diagnosis of orbital myxoid liposarcoma underwent surgical treatment in our department. Since the patient's family pedigree met the clinical criteria for the diagnosis of LFS, molecular analysis was performed, which resulted in a molecular profile consistent with Li-Fraumeni syndrome. Results The patient underwent orbital exenteration extended to the upper eyelid; surgical reconstructive steps were performed to permit placement of an orbital prosthesis. Two years after primary surgery the patien…

AdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast NeoplasmsLiposarcomaMalignancyliposarcoma Li-Fraumeni syndrome orbital surgery.030218 nuclear medicine & medical imagingLi-Fraumeni Syndrome03 medical and health sciences0302 clinical medicinemedicineHumansOrbital prosthesisFamily historyMyxoid liposarcomabusiness.industryLiposarcomaGeneral Medicinemedicine.diseaseSurgeryOncologyLi–Fraumeni syndrome030220 oncology & carcinogenesisOrbital NeoplasmsFemaleLymphadenectomybusinessQuadrantectomyTumori Journal
researchProduct

Posttranslationally modified proteins as mediators of sustained intestinal inflammation.

2006

Oxidative and carbonyl stress leads to generation of N(epsilon)-carboxymethyllysine-modified proteins (CML-mps), which are known to bind the receptor for advanced glycation end products (RAGE) and induce nuclear factor (NF)-kappaB-dependent proinflammatory gene expression. To determine the impact of CML-mps in vivo, RAGE-dependent sustained NF-kappaB activation was studied in resection gut specimens from patients with inflammatory bowel disease. Inflamed gut biopsy tissue demonstrated a significant up-regulation of RAGE and increased NF-kappaB activation. Protein extracts from the inflamed zones, but not from noninflamed resection borders, caused perpetuated NF-kappaB activation in cultured…

AdultCell ExtractsMaleReceptor for Advanced Glycation End ProductsInflammationBiologyInflammatory bowel diseasep38 Mitogen-Activated Protein KinasesPathology and Forensic MedicineProinflammatory cytokineRAGE (receptor)MiceGlycationhemic and lymphatic diseasesGene expressionmedicineAnimalsCalgranulin BHumansCalgranulin AIntestinal MucosaReceptors ImmunologicReceptorProtein Kinase InhibitorsMice KnockoutMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3LysineNF-kappa Bnutritional and metabolic diseasesEndothelial Cellsmedicine.diseaseNFKB1Inflammatory Bowel DiseasesIntestinesDisease Models AnimalImmunologyCancer researchFemalemedicine.symptomProtein Processing Post-TranslationalRegular ArticlesThe American journal of pathology
researchProduct

Cellular and humoral immunity to the 60-kD heat shock protein in inflammatory bowel disease.

1997

Background: Mycobacteria have been considered a possible etiological agent in Crohn’s disease. Since cross-reactivity between epitopes of mycobacterial and self-heat shock protein might represent a potential disease mechanism, we determined the cellular and humoral immune responses to the mycobacterial and the human 60-kD heat shock protein, as well as various control antigens. Methods: We studied samples from 19 patients with Crohn’s disease, 12 patients with ulcerative colitis, and from 19 healthy individuals. T cell responses were studied using a standard proliferation assays to purified recombinant mycobacterial and human 60-kD heat shock protein. Antibody levels were measured by establ…

AdultCellular immunityEnzyme-Linked Immunosorbent AssayBiologymedicine.disease_causeLymphocyte ActivationInflammatory bowel diseaseMicrobiologyAutoimmunityImmune systemAntigenCrohn DiseaseHeat shock proteinmedicineHumansLymphocytesAntigens BacterialGastroenterologyChaperonin 60Mycobacterium tuberculosismedicine.diseaseShock (circulatory)Case-Control StudiesHumoral immunityImmunologyAntibody FormationColitis Ulcerativemedicine.symptomDigestion
researchProduct

Lymphocyte subpopulations in solvent-exposed workers.

1986

To estimate the cellular immune response of workers highly exposed to mixtures of organic solvents, subpopulations of peripheral blood lymphocytes (PBLs) were analyzed. For this, the PBLs of nine floorers (aged 25–58 years, exposure time 8–35 years) were subsequently labelled with monoclonal antibodies OKT 4, OKT 8, OKT 11, anti-Leu 7 and anti-Leu 12. Analysis was made by a FACS IV cell sorter (Becton-Dickinson, USA). The control group consisted of matched pairs of healthy donors. In the exposed group we found a decrease in the OKT 11 (all) T cell fraction, a decrease in the OKT 4 helper cells, an increase in the anti-Leu 7 positive cells, mostly natural killer cells, an important increase …

AdultCellular immunityImmunity CellularLymphocytosismedicine.drug_classT cellLymphocytePublic Health Environmental and Occupational HealthAir Pollutants OccupationalBiologyMiddle AgedMonoclonal antibodymedicine.diseaseImmune systemmedicine.anatomical_structureImmunologymedicineSolventsHumansLymphocytesmedicine.symptomAplastic anemiaImmunodeficiencyInternational archives of occupational and environmental health
researchProduct

Immunohistochemical Investigation of Metastasis-Related Chemokines in Deep-Infiltrating Endometriosis and Compromised Pelvic Sentinel Lymph Nodes

2015

Endometriosis is a prevalent benign disease, despite sharing several similarities with malignancies, such as the possibility of lymphatic spread. In malignancies, chemokines play a sovereign role in the process of metastasis. Metastasis-related chemokine axes have not yet been assessed in deep-infiltrating endometriosis (DIE), and this investigation was the aim of our study. The expression of these chemokines was investigated by immunohistochemistry in rectovaginal DIE lesions and in matched pelvic sentinel lymph nodes (PSLNs) of patients with endometriosis (n = 27), and their expression in the eutopic endometrium (EE) of endometriosis-free women (n = 20) was used as controls. Their stainin…

AdultChemokinePathologymedicine.medical_specialtyEndometriosisEndometriosislymphatic spreadMetastasisEndometriumYoung AdultCell MovementLymphatic SpreadmedicineHumansEutopic endometriumpelvic sentinel lymph nodeRetrospective StudiesbiologySentinel Lymph Node Biopsybusiness.industrychemokineendometriosiObstetrics and GynecologyMiddle Agedmedicine.diseaseImmunohistochemistryDeep infiltrating endometriosisbiology.proteinImmunohistochemistryFemaleLymph NodesLymphChemokinesbusinessBiomarkersReproductive Sciences
researchProduct

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

2010

The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) were given 240 μg/kg plerixafor SC 9-11 h before apheresis. A total of 78.3% (47/60) received G-CSF for 4 days before plerixafor administration; 76.6% of those (36/47) yielded at least 2.0 × 10(6) CD34(+) cells/μL. The median cell yield was 3.35 × 10(6) CD34+ cells/kg (0-29.53). Nine patients received plerixafor alone or with G-CSF for less than 4 days mobilizing a median of 3.30 …

AdultCompassionate Use TrialsMalemedicine.medical_specialtyBenzylaminesAdolescentStem cell mobilizationmedicine.medical_treatmentCyclamsPoor mobilizersGermanYoung AdultHeterocyclic CompoundsGermanyGranulocyte Colony-Stimulating FactormedicineHumansIntensive care medicineChildAgedTransplantationChemotherapybusiness.industryPlerixaforLymphoma Non-HodgkinHematopoietic Stem Cell TransplantationCompassionate UseHematologyMiddle AgedCombined Modality TherapyHodgkin Diseasehumanitieslanguage.human_languageHematopoietic Stem Cell MobilizationTreatment OutcomeChild PreschoollanguageBlood Component RemovalFemalebusinessMultiple Myelomamedicine.drugBone marrow transplantation
researchProduct